Last updated: September 8, 2026
CINRYZE is a plasma-derived C1 esterase inhibitor manufactured by Takeda for routine prophylaxis against hereditary angioedema (HAE) attacks. The product gained first-mover advantage after FDA approval in 2008, but its commercial position weakened after the entry of subcutaneous prophylactic products, especially Takhzyro and Haegarda. CINRYZE retains regulatory and clinical relevance, but its long-term growth profile is constrained by intravenous administration, plasma-derived manufacturing, supply interruptions, and the expiration of U.S. biologic exclusivity in 2020.
What is CINRYZE and what is its FDA regulatory status?
CINRYZE contains human plasma-derived C1 esterase inhibitor, also known as C1-INH. It is approved for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.
| Regulatory attribute |
CINRYZE |
| Active ingredient |
C1 esterase inhibitor, human |
| Product type |
Plasma-derived biologic |
| FDA application |
BLA 125285 |
| Original approval |
October 14, 2008 |
| Indication |
Routine prophylaxis against HAE attacks |
| Administration |
Intravenous infusion |
| Original sponsor |
ViroPharma |
| Current commercial owner |
Takeda |
| U.S. biologic exclusivity |
Expired in October 2020 |
| Therapeutic class |
C1-INH replacement therapy |
The original FDA approval covered patients aged 13 years and older. FDA later expanded the label to include children aged 6 years and older. CINRYZE is not an acute rescue treatment for an established HAE attack. Its commercial role is preventive therapy administered on a regular schedule.[1]
The product originated with ViroPharma, which was acquired by Shire in 2014 for approximately $4.2 billion. Takeda acquired Shire in 2019, transferring CINRYZE into Takeda’s rare-disease portfolio.[2][3]
How has CINRYZE revenue changed over time?
CINRYZE revenue increased after its approval as HAE diagnosis and prophylactic treatment expanded, but the product later encountered commercial and operational pressure. Shire’s public reporting grouped CINRYZE with its HAE franchise in some periods and disclosed product-level figures inconsistently. Takeda subsequently reduced brand-level reporting, making a complete current revenue series unavailable from company filings.
Historical financial trajectory
| Period |
Financial and commercial development |
| 2008-2013 |
CINRYZE established the first major U.S. prophylactic C1-INH franchise |
| 2014 |
ViroPharma acquisition by Shire increased the value of the HAE portfolio |
| 2015-2016 |
HAE sales expanded through broader diagnosis and greater use of prophylaxis |
| 2017 |
Manufacturing and supply constraints affected CINRYZE availability |
| 2018 |
Takhzyro launched, creating a direct prophylaxis competitor with subcutaneous delivery |
| 2019 |
Takeda completed its acquisition of Shire |
| 2020 |
U.S. biologic exclusivity expired; newer prophylactic options gained market share |
| 2021-present |
Takeda continued commercializing CINRYZE, while public disclosures emphasized broader rare-disease and HAE portfolios |
CINRYZE’s strongest commercial period occurred before the rapid adoption of subcutaneous prophylaxis. The product benefited from its established clinical history, physician familiarity, and use in patients who required regular C1-INH replacement. Its limitations became more important as alternatives offered less burdensome administration.
The main financial drivers are:
- HAE prevalence and diagnosis rates.
- The proportion of patients receiving routine prophylaxis.
- Reimbursement for plasma-derived biologics.
- Patient preference for intravenous versus subcutaneous administration.
- Manufacturing capacity and plasma supply.
- Competition from Takhzyro, Haegarda, and oral kallikrein inhibition.
- Takeda’s portfolio allocation and promotional priorities.
What caused CINRYZE’s commercial decline?
CINRYZE’s market position weakened for structural rather than purely patent-related reasons.
Intravenous administration
CINRYZE is administered intravenously, generally every three to four days for routine prophylaxis. This creates a treatment burden for patients compared with subcutaneous or oral alternatives. Home infusion is possible, but it requires training, supplies, venous access, and consistent product availability.
Supply interruptions
CINRYZE experienced manufacturing and supply constraints, including a significant disruption reported by Shire in 2017. The issue affected the company’s ability to satisfy demand and increased the risk that physicians would transition patients to competing therapies.[4]
For plasma-derived products, manufacturing capacity is a competitive asset. The product requires plasma collection, viral inactivation, purification, quality control, and batch release. A competitor with a reliable supply chain can gain accounts even when the incumbent has strong clinical recognition.
New prophylactic therapies
Takhzyro, a long-acting plasma kallikrein inhibitor, received FDA approval in 2018 and is administered subcutaneously every two weeks for many patients. Haegarda, a subcutaneous C1-INH product, was approved in 2017. Orladeyo, an oral kallikrein inhibitor, entered the market in 2020.[5][6][7]
These products changed treatment selection. CINRYZE competes against therapies that can reduce infusion frequency or eliminate intravenous administration.
How does CINRYZE compare with Takhzyro, Haegarda, Berinert, and Orladeyo?
| Product |
Manufacturer |
Modality |
Typical administration |
Primary competitive impact |
| CINRYZE |
Takeda |
Plasma-derived C1-INH |
Intravenous, regular prophylaxis |
Established prophylaxis product with high administration burden |
| Haegarda |
CSL Behring |
Plasma-derived C1-INH |
Subcutaneous, twice weekly |
Offers the same replacement mechanism with subcutaneous delivery |
| Berinert |
CSL Behring |
Plasma-derived C1-INH |
Intravenous |
Competes mainly in acute treatment and certain prophylactic settings |
| Takhzyro |
Takeda |
Monoclonal antibody against plasma kallikrein |
Subcutaneous, generally every two weeks |
Major internal and external competitor to CINRYZE |
| Orladeyo |
BioCryst |
Oral plasma kallikrein inhibitor |
Once daily oral administration |
Competes through convenience and non-injectable dosing |
Takhzyro is the most important competitive comparison because it is also owned by Takeda and addresses the same HAE prophylaxis market. Takeda has an economic incentive to shift its HAE portfolio toward the product with stronger growth, longer commercial runway, and lower administration burden.
CINRYZE retains potential advantages for patients who prefer C1-INH replacement, have clinical reasons to avoid kallikrein inhibition, or require a product with extensive historical use. Those advantages do not fully offset the convenience gap.
What patents protect CINRYZE?
CINRYZE is protected primarily through biologic regulatory exclusivity, product-specific manufacturing know-how, trade secrets, and any issued patents covering C1-INH compositions, purification, stabilization, formulation, or therapeutic use.
U.S. patent and exclusivity position
CINRYZE is licensed under a biologics license application rather than approved through a conventional abbreviated new drug application. As a result, it does not have the same Orange Book patent-listing structure as a small-molecule drug.
| Protection category |
CINRYZE status |
| U.S. biologic regulatory exclusivity |
Expired in October 2020 |
| Orange Book listing |
Not the primary U.S. reference for this biologic |
| Purple Book relevance |
Yes |
| Patent-based protection |
Potentially relevant to manufacturing, formulation, and use |
| Biosimilar pathway |
Legally available under the Public Health Service Act |
| Approved U.S. biosimilar |
None identified in the cited FDA materials |
The Biologics Price Competition and Innovation Act provides 12 years of reference-product exclusivity for qualifying biologics. CINRYZE’s reference-product exclusivity therefore expired 12 years after the October 2008 approval date.[8]
The absence of remaining regulatory exclusivity does not eliminate patent or manufacturing barriers. Plasma-derived C1-INH products are difficult to replicate because a prospective competitor must establish a reliable source of human plasma, a validated purification process, viral safety controls, consistent potency, and comparable clinical performance.
Are there biosimilar or generic risks for CINRYZE?
There is no conventional generic substitution pathway for CINRYZE because it is a biologic. A competitor would need to pursue a biosimilar or related biological-product pathway, not a standard ANDA route.
No FDA-approved biosimilar to CINRYZE is identified in the FDA Purple Book materials cited here.[9] The practical risk remains longer term because:
- biologic exclusivity has expired;
- the active ingredient is clinically established;
- HAE is a high-value orphan market;
- payer pressure can support lower-cost alternatives; and
- manufacturers with plasma and biologics infrastructure can pursue C1-INH products.
The technical barriers are substantial. A biosimilar sponsor would need to demonstrate analytical similarity, manufacturing consistency, immunogenicity control, and sufficient clinical evidence. Plasma-derived products also raise questions about source material, process controls, and product comparability.
What patent litigation and Paragraph IV challenges affect CINRYZE?
CINRYZE has no Orange Book Paragraph IV litigation profile comparable to a small-molecule product. Paragraph IV certification applies to patents listed in the Orange Book for an abbreviated new drug application. CINRYZE is a biologic licensed under a BLA, so biosimilar disputes proceed under the BPCIA patent-exchange and litigation framework rather than the Hatch-Waxman Paragraph IV process.[8]
The public commercial risk is therefore more likely to arise from:
- a future biosimilar BLA;
- patent disputes involving manufacturing or formulation claims;
- regulatory challenges to related C1-INH products; or
- payer-driven substitution among clinically differentiated HAE therapies.
There is no cited evidence of a current U.S. biosimilar litigation campaign against CINRYZE.
What formulations and manufacturing barriers protect CINRYZE?
CINRYZE’s principal defensibility is operational. The product uses human plasma-derived protein, and its manufacturing process must control:
- plasma donor screening;
- viral inactivation and removal;
- purification yield;
- protein stability;
- potency and purity;
- batch-to-batch consistency;
- cold-chain distribution; and
- release testing.
These requirements create a higher entry threshold than for a conventional tablet. They also increase the consequences of manufacturing failures. In 2017, Shire’s reported CINRYZE supply problems demonstrated that the same complexity can weaken the incumbent’s commercial position.[4]
Manufacturing know-how is difficult for competitors to observe and may remain valuable after patent expiration. It is also difficult to enforce against independent development because a competitor can use a different process if it meets regulatory standards.
What is the geographic coverage of CINRYZE?
CINRYZE has had international regulatory and commercial exposure, but the United States has been the central market because of HAE diagnosis, specialty-pharmacy infrastructure, and reimbursement economics. Market access outside the U.S. depends on country-specific approvals, pricing negotiations, plasma-derived product requirements, and local treatment guidelines.
The commercial value of CINRYZE is concentrated in markets with:
- recognized HAE diagnostic networks;
- reimbursement for preventive biologics;
- access to specialty infusion services; and
- sufficient availability of plasma-derived products.
The product’s international position is weaker where subcutaneous therapies receive favorable reimbursement or where infusion infrastructure is limited.
How strong is the CINRYZE patent estate?
CINRYZE has a moderate-to-weak long-term patent position when measured against newer biologics with unexpired composition-of-matter claims and extended exclusivity. Its main strengths are regulatory history, manufacturing complexity, physician familiarity, and Takeda’s HAE commercial platform.
Its weaknesses are more material:
- U.S. biologic exclusivity expired in 2020.
- The product is vulnerable to administration-burden comparisons.
- No Orange Book strategy provides a clear Hatch-Waxman delay mechanism.
- Competing prophylactic products have improved convenience.
- Takeda’s own Takhzyro portfolio may receive greater strategic priority.
- Supply interruptions damaged confidence in continuity of treatment.
The estate is stronger as a manufacturing and know-how position than as a straightforward patent-based exclusivity position.
What generic launch scenarios exist for CINRYZE?
Scenario 1: No near-term biosimilar
This remains the most likely commercial scenario because of the technical and clinical complexity of plasma-derived C1-INH products. CINRYZE would continue to decline gradually as existing patients switch to newer prophylactic therapies.
Scenario 2: C1-INH biosimilar or follow-on product
A lower-priced follow-on could pressure reimbursement and reduce CINRYZE’s share, particularly in price-sensitive payer channels. The impact would depend on interchangeability, physician confidence, supply reliability, and contracting.
Scenario 3: Therapeutic substitution without biosimilar entry
This is the most immediate competitive threat. Takhzyro, Haegarda, Orladeyo, and other HAE therapies can reduce CINRYZE demand without challenging its patents. The market can contract through clinical switching rather than generic launch.
Key Takeaways
- CINRYZE was FDA-approved in 2008 as a plasma-derived C1-INH for routine HAE prophylaxis.
- Takeda acquired the product through its 2019 acquisition of Shire.
- U.S. biologic exclusivity expired in October 2020.
- The product’s principal commercial weaknesses are intravenous administration, supply history, and competition from subcutaneous and oral therapies.
- Takhzyro is CINRYZE’s most important competitive benchmark and is also owned by Takeda.
- CINRYZE does not have a conventional Orange Book or Paragraph IV litigation profile.
- No FDA-approved CINRYZE biosimilar is identified in the cited materials.
- Manufacturing complexity and plasma supply remain meaningful barriers to entry.
- The near-term revenue trajectory is more likely to be shaped by therapeutic switching than by a conventional generic launch.
- CINRYZE’s strongest protections are regulatory history, manufacturing know-how, and clinical familiarity rather than unexpired U.S. regulatory exclusivity.
FAQs
When did CINRYZE lose U.S. biologic exclusivity?
CINRYZE’s 12-year U.S. reference-product exclusivity expired in October 2020, based on its October 14, 2008 FDA approval.
Is CINRYZE listed in the Orange Book?
CINRYZE is a biologic licensed under a BLA, so the Orange Book is not the primary patent-listing framework. The Purple Book and BPCIA procedures are more relevant.
Can a company launch a generic version of CINRYZE?
A conventional generic cannot be approved through the standard ANDA pathway. A competitor would generally need to pursue a biosimilar or related biologic approval.
Which HAE drug poses the greatest threat to CINRYZE sales?
Takhzyro poses the greatest direct threat because it is approved for routine HAE prophylaxis, uses subcutaneous administration, and is marketed by the same company, Takeda.
Does CINRYZE still have commercial value after patent and exclusivity expiration?
Yes. Its value is supported by clinical familiarity, established manufacturing, reimbursement relationships, and the difficulty of producing plasma-derived C1-INH. Its growth potential is limited by newer, more convenient prophylactic therapies.
References
-
U.S. Food and Drug Administration. (2008). CINRYZE prescribing information and approval history. FDA.
-
ViroPharma Inc. (2013). ViroPharma annual report and acquisition materials. U.S. Securities and Exchange Commission.
-
Shire plc. (2014). Shire completes acquisition of ViroPharma. Shire plc.
-
Shire plc. (2017). Annual report 2017. Shire plc.
-
U.S. Food and Drug Administration. (2017). HAEGARDA approval announcement. FDA.
-
U.S. Food and Drug Administration. (2018). TAKHZYRO approval announcement. FDA.
-
U.S. Food and Drug Administration. (2020). ORLADEYO approval announcement. FDA.
-
U.S. Congress. (2010). Biologics Price Competition and Innovation Act of 2009, 42 U.S.C. § 262.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. FDA.
